Friday, August 10, 2007
Cincinnati-based CRO Kendle reported nearly a 60% jump in service revenue during the second quarter of 2007 compared with last year’s same period. The company had net revenue of $97.8 million for the quarter compared with $62.1 million in 2006. Kendle reported second quarter earnings per share of $.29 and total income from operations of $10.9 million.
Pfizer reported positive results from a phase III trial of maraviroc for the treatment of HIV. This 48-week trial was dubbed MERIT (maraviroc versus Efavirenz Regimens as Initial Therapy) and enrolled CCR5-tropic HIV-1 infected subjects who had never received antiretroviral therapy and had no evidence of resistance to the drugs used in the study. MERIT was designed to compare maraviroc (300 mg twice daily) to efavirenz, standard of care, (600 mg once daily), both dosed in combination with zidovudine/lamivudine.
China and India have joined a World Health Organization (WHO)-run international database of clinical trials. Both countries had already recently established their own databases but had to align those registries with a set of standard criteria set forth by a team of experts at the United Nations.
In a move that will take Reston, Va.-based contract research organization (CRO) PRA International off the public market, the company has entered into an agreement to be purchased by Genstar Capital, a private equity group based in San Francisco. The deal is valued at $790 million.
Waltham, Mass.-based Phase Forward, a provider of electronic data capture (EDC), drug safety and data management solutions for clinical trials, reported second quarter revenues rose 28% to $31.5 million and profits doubled.
By Dragana Maca Kastratovic, M.D.